Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab

Archives of Dermatology

Volumn 146, Issue 12, 2010, Pages 1343-1345

  Sánchez Ramón, Silvia ^a   Alecsandru, Diana ^a   Padilla, Belén ^a   Izquierdo, José Antonio Avilés ^a   Fernández Cruz, Eduardo ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; CEFUROXIME; CLINDAMYCIN; CORTICOSTEROID; DOXYCYCLINE; ERYTHROMYCIN STEARATE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INFLIXIMAB; ISONIAZID; ISOTRETINOIN; MINOCYCLINE; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VIRUS RNA;

ABDOMEN; ACNE CONGLOBATA; ADULT; ANTIBIOTIC THERAPY; ANUS; ARTICLE; AXILLA; CASE REPORT; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG WITHDRAWAL; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FISTULA; GLUTEUS MAXIMUS MUSCLE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; LYMPHADENOPATHY; MAINTENANCE THERAPY; MALE; MINIMALLY INVASIVE SURGERY; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; SCAR; SINUS TRACT FISTULA; SKIN DEFECT; SUPPURATIVE HIDRADENITIS; THORAX; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS CONTROL; VIRUS LOAD;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HIDRADENITIS SUPPURATIVA; HIV ANTIBODIES; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650463941     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2010.372     Document Type: Article

References (15)

1. Thielen AM, Barde C, Saurat JH. Long-term infliximab for severe hidradenitis suppurativa. Br J Dermatol. 2006;155(5):1105-1107.
2. Gaylis N. Infliximab in the treatment of an HIV positive patient with Reiter's syndrome. J Rheumatol. 2003;30(2):407-411.
3. Bartke U, Venten I, Kreuter A, et al. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab. Br J Dermatol. 2004; 150(4):784-786.
4. Beltrán B, Nos P, Bastida G, Iborra M, Hoyos M, Ponce J. Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease. Gut. 2006;55(11):1670-1671.
5. Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. 2004;18(2):257-264.
6. Ting PT, Koo JY. Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients. Int J Dermatol. 2006; 45(6):689-692.
7. Wallis RS. Anti-tuberculosis treatment and infliximab. Respir Med. 2005;99(12): 1620-1622.
8. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double- blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62(2): 205-217.
9. Haslund P, Lee RA, Jemec GB. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm Venereol. 2009;89(6):595-600.
10. Lebwohl B, Sapadin AN. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2003;49(5)(suppl):S275-S276.
11. Poulin Y. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept. J Cutan Med Surg. 2009;13(4): 221-225.
12. Sotiriou E, Apalla Z, Vakirlis E, Ioannides D. Efficacy of adalimumab in recalcitrant hidradenitis suppurativa. Eur J Dermatol. 2009;19(2):180-181.
13. Walker RE, Spooner KM, Kelly G, et al. Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1. J Infect Dis. 1996;174(1):63-68.
14. Ferkolj I, Ihan A, Markovic S, Veceric Z, Pohar M. Infliximab reduces the number of activated mucosal lymphocytes in patients with Crohn's disease. J Gastrointestin Liver Dis. 2006;15(3):231-235.
15. Pawlik A, Ostanek L, Brzosko I, et al. Therapy with infliximab decreases the CD4+CD28- T cell compartment in peripheral blood in patients with rheumatoid arthritis. Rheumatol Int. 2004;24(6):351-354.